Description
Non-Fucosylated Anti-Human CD3 (Muromonab-CD3) is a glycosylation-modified therapeutic biobetter antibody.
Antibody Indication
Reversal of kidney transplant rejection
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD3 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD3D
Full Name
CD3d Molecule
Background
CD3D (CD3d Molecule) is a Protein Coding gene.
Diseases associated with CD3D include Immunodeficiency 19 and T-B+ Severe Combined Immunodeficiency Due To Cd3delta/Cd3epsilon/Cd3zeta.
Among its related pathways are G-protein signaling N-RAS regulation pathway and Toll-like receptor signaling pathway.
Gene Ontology (GO) annotations related to this gene include protein heterodimerization activity and transmembrane signaling receptor activity.
An important paralog of this gene is CD3G.
Alternative Names
Teplizumab;876387-05-2;MGA031;hOKT3gamma1(Ala-Ala);CD3D;CD3d molecule, delta (CD3-TCR complex);CD3d antigen, delta polypeptide (TiT3 complex), T3D;T-cell surface glycoprotein CD3 delta chain;CD3 delta;OKT3, delta chain;CD3 antigen, delta subunit;T-cell r
Gene ID
915
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
Muromonab-CD3
Description
This clone was generated using a stable CHO cell line with the FUT8 knockout gene. It was 100% non-fucosylated. In an in vitro cell-based ADCC assay, the afucosylated antibody clone showed significantly higher ADCC activity compared to its wild type version. The binding affinity of the non-fucosylated Fc variant antibody to Fc receptor is much higher than than the same antibody with fucosylated Fc. Robust and stable production of qualitative fully non-fucosylated therapeutic antibodies is achieved.
Antibody Indication
Reversal of kidney transplant rejection
